Avacta Share Discussion Threads

[nobbygnome] 06/2/2019 16:57

Chart looking good for a further breakout from the recent high....

[cf456] 06/2/2019 15:22

Great value down here.

finnCap's recent broker note has a 125p target vs current 45.8p mid. Significant upside to that level.

And greater upside still to reach the levels that comparators are rated at.

[1i1i1i] 06/2/2019 15:17

MMs getting squeezed with no stock around, forced to move the price up on small volume.

[danatkins] 06/2/2019 13:54

1B MC and that's not even being hyperbolic

[1i1i1i] 06/2/2019 13:25

Looking at these deals it's not hard to see us in the not too distant future as a billion dollar company, the current market cap is around a ludicrous 50m so I make that a 20 bagger. In my ISA you go AVCT :-)

[cf456] 06/2/2019 13:21

"Investment summary: AVCT has made considerable progress towards its goal of having a number of commercial partnerships for its Affimer technology, as well as developing its own proprietary Affimer-based drugs and growing a separate, profitable reagents business.

The rising number of collaboration deals being discussed and signed is clear indication of the long-term value of its Affimer technology, which the market is currently only just beginning to recognise."

[cf456] 06/2/2019 13:12

"Confirmation that Moderna has exercised its option to enter into exclusive licence agreements for selected therapeutic Affimer candidates for clinical development is very positive for AVCT. It is a strong indication that AVCT delivers Affimers with activity against Moderna’s targets to an extent that they are worthy of making a considerable investment in clinical trials."

"Moreover, a number of major pharma/biotech companies are nearing the end of a significant period of validation of Affimers against their specific targets, and it is likely that more deals will be announced in 2019."

[patientcapital] 06/2/2019 13:11

It's like the market is asleep at the wheel.

[cf456] 06/2/2019 13:07

Looks like the note has brought in some buying again.

[the drewster] 05/2/2019 14:25

Not available but know a man who is.

[nobbygnome] 05/2/2019 13:44

I have got my invitation to the science day 👍👍! I think my Pharma experience swung it in my favour..... Anyone else going from here?

[1i1i1i] 05/2/2019 12:55

Just topped up, ridiculously low share price against revenues incoming, than you Mr Market Maker.

[danatkins] 04/2/2019 12:53

Yes it did and at the time they sold Optim (not sure on spelling). Then is not now. Ducks are lining up IMO

[cf456] 04/2/2019 12:53

From today's finnCap note:

"Financial implications. The original research collaboration (May 2015), stipulated that Moderna had the option to enter into exclusive license agreements for selected
therapeutic Affimer candidates for clinical development and in each case Avacta would
be entitled to milestone payments, the total value of which could reach several tens of millions of dollars. Given that Moderna has selected a single target, this gives some guidance as to the milestone amounts that might be expected. We expect the first
milestone payment to be received in 2019, when the drug enters Phase I clinical trials."

[lantanatony] 04/2/2019 12:44

Maybe you are correct but the share price did rise substantially at the time.
Surely there must be an interim payment on exercise of option?
Let's see what the next deal brings.
Hopefully more detail.

[danatkins] 04/2/2019 12:32

Don't expect too much on this deal Tony. It was their first deal done in 2015. At least Moderna are happy to take further. That's the main news here.

[lantanatony] 04/2/2019 12:13

Very positive news from Avacta today but once again very vague on revenue details.
That word potential keeps reoccurring!
But positive all the same so that's good.

[danatkins] 04/2/2019 11:56

Anyone using finncap's target price as area to offload will be giving shares away to II's IMO

[danatkins] 04/2/2019 11:45

Ignore finncap's target it very wrong!

[cf456] 04/2/2019 11:34

The share price has to multiply 2.7x from the current 46.5p mid to get to finnCap's increased target.

[hampton58] 04/2/2019 11:32

AgreeOne would expect several new license dealsAs both Moderna and LG have done extensive DD etc on Avacta and the current share price does not reflect at all the potential and the very realistic scenario of several more $300 mill license deals being signed this year, the OEM's needs to find new revenue sources and Avacta is attracting a lot of interest .If you would to apply a US listed immuno Oncology valuation , then you have a share price of 250pOnce the human trials starts , there will be no stock available. None !!!